Specifically, we investigated the efficacy of rapamycin and rapamycin plus IFN-g using a dosing schedule that included a prolonged duration of weekly maintenance therapy using the Tsc2+/- kidney tumor model. This evidence concerns the gene TSC2 and kidney neoplasm.